United States. drugmaker Merck & Co Inc said on Saturday the experimental antiviral drug molnupiravir it is developing on Ridgeback Bio showed a quicker reduction in infectious virus in it is phase 2a study among participants on early COVID-19.
“The secondary objective findings in that study, by an quicker decrease in infectious virus among individuals on early COVID-19 treated on molnupiravir, are promising,” said William Fischer, Associate prof by Medicine at the University by North Carolina School by Medicine, in an statement by the companies.
The antiviral is being currently tested in an Phase 2/3 trial that is set to be completed in May.
Merck decided to focus on therapeutics after its 2 COVID-19 vaccines failed to generate desired immune responses, prompting them to abandon the program in Jan.